Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)
China
· Delayed Price · Currency is CNY 83.01
+0.02 (0.02%)
Feb 28, 2025, 2:44 PM CST
Xiamen Amoytop Biotech Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Cash & Equivalents | - | 412.96 | 301.24 | 285.42 | 197.16 | Upgrade
|
| Trading Asset Securities | - | 257.08 | 270.78 | 196.38 | 268.22 | Upgrade
|
| Cash & Short-Term Investments | 584.55 | 670.04 | 572.02 | 481.8 | 465.38 | Upgrade
|
| Cash Growth | -12.76% | 17.14% | 18.73% | 3.53% | 126.04% | Upgrade
|
| Accounts Receivable | - | 441.02 | 223.05 | 206.28 | 185 | Upgrade
|
| Other Receivables | - | 17.87 | 20.17 | 21.67 | 11.99 | Upgrade
|
| Receivables | - | 458.9 | 243.22 | 227.94 | 196.99 | Upgrade
|
| Inventory | - | 187.02 | 129.73 | 116.49 | 99.62 | Upgrade
|
| Other Current Assets | - | 24.24 | 10.64 | 8.19 | 10.81 | Upgrade
|
| Total Current Assets | - | 1,340 | 955.61 | 834.42 | 772.8 | Upgrade
|
| Property, Plant & Equipment | - | 490.85 | 389.77 | 192.92 | 126.74 | Upgrade
|
| Other Intangible Assets | - | 191.54 | 121.69 | 146.91 | 172.28 | Upgrade
|
| Long-Term Deferred Tax Assets | - | 43.66 | 47.18 | 34.96 | 24.97 | Upgrade
|
| Long-Term Deferred Charges | - | 176.7 | 229.25 | 169.14 | 78.24 | Upgrade
|
| Other Long-Term Assets | - | 112.98 | 26.05 | 44.99 | 16.24 | Upgrade
|
| Total Assets | - | 2,356 | 1,770 | 1,424 | 1,193 | Upgrade
|
| Accounts Payable | - | 39.73 | 50.91 | 8.14 | 7.15 | Upgrade
|
| Accrued Expenses | - | 244.46 | 159.55 | 120.4 | 60.94 | Upgrade
|
| Short-Term Debt | - | - | - | 10 | 18.92 | Upgrade
|
| Current Portion of Leases | - | 4.16 | 4.18 | 5.79 | - | Upgrade
|
| Current Income Taxes Payable | - | 48.95 | 41.97 | 24.42 | 8.73 | Upgrade
|
| Current Unearned Revenue | - | 60.05 | 7.23 | 5.18 | 3.34 | Upgrade
|
| Other Current Liabilities | - | 6.31 | 4.05 | 3.3 | 15.86 | Upgrade
|
| Total Current Liabilities | - | 403.66 | 267.89 | 177.23 | 114.94 | Upgrade
|
| Long-Term Leases | - | 3.76 | 5.56 | 9.37 | - | Upgrade
|
| Long-Term Unearned Revenue | - | 40.62 | 47.68 | 51.25 | 56.84 | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | 0.41 | 15.15 | 5.54 | 3.07 | Upgrade
|
| Other Long-Term Liabilities | - | 31.25 | 25.99 | 19.53 | 17.48 | Upgrade
|
| Total Liabilities | - | 479.69 | 362.27 | 262.91 | 192.33 | Upgrade
|
| Common Stock | - | 406.8 | 406.8 | 406.8 | 406.8 | Upgrade
|
| Additional Paid-In Capital | - | 397.04 | 397.04 | 397.04 | 397.04 | Upgrade
|
| Retained Earnings | - | 1,073 | 603.76 | 357.42 | 196.56 | Upgrade
|
| Shareholders' Equity | 2,265 | 1,876 | 1,408 | 1,161 | 1,000 | Upgrade
|
| Total Liabilities & Equity | - | 2,356 | 1,770 | 1,424 | 1,193 | Upgrade
|
| Total Debt | 9.9 | 7.92 | 9.74 | 25.16 | 18.92 | Upgrade
|
| Net Cash (Debt) | 574.65 | 662.11 | 562.28 | 456.63 | 446.46 | Upgrade
|
| Net Cash Growth | -13.21% | 17.76% | 23.14% | 2.28% | 206.23% | Upgrade
|
| Net Cash Per Share | 1.41 | 1.63 | 1.39 | 1.13 | 1.11 | Upgrade
|
| Filing Date Shares Outstanding | 408.36 | 406.8 | 406.8 | 406.8 | 406.8 | Upgrade
|
| Total Common Shares Outstanding | 406.8 | 406.8 | 406.8 | 406.8 | 406.8 | Upgrade
|
| Working Capital | - | 936.53 | 687.72 | 657.19 | 657.86 | Upgrade
|
| Book Value Per Share | 5.57 | 4.61 | 3.46 | 2.85 | 2.46 | Upgrade
|
| Tangible Book Value | 2,085 | 1,685 | 1,286 | 1,014 | 828.12 | Upgrade
|
| Tangible Book Value Per Share | 5.13 | 4.14 | 3.16 | 2.49 | 2.04 | Upgrade
|
| Buildings | - | 135.53 | 118.65 | 21.31 | 22.03 | Upgrade
|
| Machinery | - | 319.97 | 271.83 | 177.83 | 173.49 | Upgrade
|
| Construction In Progress | - | 183.72 | 135.81 | 118 | 68.43 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.